Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Jan;34(1):43–48. doi: 10.1007/BF01741323

Immunotherapy of B lymphoma by anti-idiotype antibodies: Characterization of variant tumour cells appearing a long time after the initial tumour inoculation

Mahmoud Taya 1,✉, Joseph Haimovich 1
PMCID: PMC11038697  PMID: 1760810

Abstract

Immunotherapy of a murine B-cell lymphoma by antibodies to idiotypic determinants of its IgM, resulted in surviving tumour-free mice. Several of these mice, however, did develop tumours a long time after the initial inoculation of the tumour cells, or upon rechallange of the survivors with B-lymphoma cells. The presence of tumour cells during this long latent period may have been due to the development in the host of an anti-idiotype immune response. These late-developing tumours were detected by a radioimmunoassay and characterized by immunofluorescent staining and sodium dodecyl sulphate/polyacrylamide gel electrophoresis. Cells of some late-developing tumours lost the idiotype recognized by the antibodies used for the immunotherapy. Several of these tumours expressed IgM on the cell surface, while others did not, because of the absence of light chains. They were identical in the structure of their rearranged µ chain genes proving their derivation from the original inoculation. Cell lines obtained from the late-developing tumours differed in their tumorigenicity. The appearance of idiotype-negative tumour cells as a result of anti-idiotype immunotherapy has a great impact in our efforts to cure lymphoma by this modality.

Key words: Anti-idiotypic antibodies, Immunotherapy, B-cell lymphoma

References

  • 1.Ber R, Eriksson I. Isolation of ouabain-resistant human lymphoblastoid cell lines by multi-step selection. Mutat Res. 1979;61:411. doi: 10.1016/0027-5107(79)90147-7. [DOI] [PubMed] [Google Scholar]
  • 2.Bergman Y, Haimovich J. Characterization of a carcinogeninduced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413. doi: 10.1002/eji.1830070702. [DOI] [PubMed] [Google Scholar]
  • 3.Bergman Y, Haimovich J. B-lymphocytes contain three species of µ chains. Eur J Immunol. 1978;8:876. doi: 10.1002/eji.1830081210. [DOI] [PubMed] [Google Scholar]
  • 4.Berinstein N, Levy R. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol. 1987;139:971. [PubMed] [Google Scholar]
  • 5.Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. J Immunol. 1988;141:3227. [PubMed] [Google Scholar]
  • 6.Ciavara RP, Vitetta ES, Forman J. Growth inhibition of B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity. J Immunol. 1986;137:1371. [PubMed] [Google Scholar]
  • 7.Cleary ML, Meeker TC, Levy S, Lee E, Trela M, Sklar J, Levy R. Clustering of extensive somatic mutation in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell. 1986;44:97. doi: 10.1016/0092-8674(86)90488-5. [DOI] [PubMed] [Google Scholar]
  • 8.Fu SM, Winchester RJ, Feizi T, Walzer PK, Kunkel HG. Idiotype specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci USA. 1974;71:4487. doi: 10.1073/pnas.71.11.4487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanism involved in suppression of a mouse B cell lymphoma BCL1 . J Immunol. 1987;138:628. [PubMed] [Google Scholar]
  • 10.George AJT, Spellerberg MB, Stevenson FK. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variants of the mouse lymphoma BCL1, with different growth characteristics. J Immunol. 1988;140:1695. [PubMed] [Google Scholar]
  • 11.Ghosh SK, Bankert RB. Generation of somatic variants of a B cell hybrid mediated by a non-cytolyticInline graphic idiotype-specific T cells. J Immunol. 1989;142:409. [PubMed] [Google Scholar]
  • 12.Glennie MJ, McBride HM, Stirpe F, Thorpe PE, Worth AT, Stevenson GT. Emergance of immunoglobulin variants following treatment of a B-cell leukemia with an immunotoxin composed of anti-idiotype antibody and saporin. J Exp Med. 1987;166:43. doi: 10.1084/jem.166.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT. Bispecific F(ab′)2 antibody for the delivery of saporin in the treatment of lymphoma. J Immunol. 1988;141:3662. [PubMed] [Google Scholar]
  • 14.Hannestad K, Kao MS, Eisen HN. Cell-bound myeloma proteins on the surface of myeloma cells, potential target for the immune system. Proc Natl Acad Sci USA. 1972;69:2295. doi: 10.1073/pnas.69.8.2295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Haughton GI, Lanier L, Babcock GF, Lynes MA. Antigen-induced murine B lymphomas. II. Exploitation of the surface idiotype as tumor specific antigen. J Immunol. 1978;121:2358. [PubMed] [Google Scholar]
  • 16.Hunter WM. Handbook of experimental Immunology. 2nd edn. Oxford: Blackwell Scientific; 1973. Radioimmunoassay; p. 17.1. [Google Scholar]
  • 17.Hurwitz E, Kashi R, Burowsky D, Arnon R, Haimovich J. Site directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM. Int J Cancer. 1983;31:745. doi: 10.1002/ijc.2910310612. [DOI] [PubMed] [Google Scholar]
  • 18.Hurwitz E, Burowski D, Kashi R, Hollander N, Haimovich J. A synergistic effect between anti-neoplastic drugs in the therapy of a murine B-cell tumor. Int J Cancer. 1986;37:739. doi: 10.1002/ijc.2910370515. [DOI] [PubMed] [Google Scholar]
  • 19.Kessler SW. Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interactions of antibody-antigen complex with protein A. J Immunol. 1975;115:1617. [PubMed] [Google Scholar]
  • 20.Krolick KA, Isakson PC, Uhr JW, Vitetta ES. BCL1 a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumors. Immunol Rev. 1979;48:81. doi: 10.1111/j.1600-065x.1979.tb00299.x. [DOI] [PubMed] [Google Scholar]
  • 21.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 22.Levy R, Warnke R, Dorfman RF, Haimovich J. The monoclonality of human B cell lymphoma. J Exp Med. 1977;145:1014. doi: 10.1084/jem.145.4.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Levy S, Campbell MJ, Levy R. Functional immunoglobulin light chain genes are replaced by ongoing rearrangement of germline Vk genes to downstream Jk segments in a murine B cell line. J Exp Med. 1989;170:1. doi: 10.1084/jem.170.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lynch RG, Rohrer JW, Odermatt B, Gebel HM, Autry JR, Hoover RG. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol Rev. 1979;48:45. doi: 10.1111/j.1600-065x.1979.tb00298.x. [DOI] [PubMed] [Google Scholar]
  • 25.Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38c-13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma. 1985;4:191. doi: 10.1089/hyb.1985.4.191. [DOI] [PubMed] [Google Scholar]
  • 26.Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. Cold Spring Harbor Laboratory. New York: Cold Spring Harbor; 1982. p. 382. [Google Scholar]
  • 27.Meeker TC, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312:1658. doi: 10.1056/NEJM198506273122602. [DOI] [PubMed] [Google Scholar]
  • 28.Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65:1349. [PubMed] [Google Scholar]
  • 29.Melchers F, Andersson J. Synthesis, surface deposition and secretion of immunoglobulin M in bone marrow derived lymphocytes before and after mitogen stimulation. Transplant Rev. 1973;14:76. doi: 10.1111/j.1600-065x.1973.tb00103.x. [DOI] [PubMed] [Google Scholar]
  • 30.Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
  • 31.Nelson KJ, Haimovich J, Perry RP. Characterization of productive and sterile transcripts from the immunoglobulin heavy chain locus: processing of µm and µs mRNA. Mol Cell Biol. 1983;3:1317. doi: 10.1128/mcb.3.7.1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nowell PC. The clonal evaluation of tumor cell population. Science. 1976;194:23. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  • 33.Perek Y, Hurwitz E, Burowski D, Haimovich J. Immunotherapy of a murine B-cell tumor with antibodies and F(ab′)2 against idiotype determinants of its cell surface IgM. J Immunol. 1983;131:1600. [PubMed] [Google Scholar]
  • 34.Peto R, Pike CM, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Logrank test. Br J Cancer. 1977;35:1. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rankin EM, Hekman A, Somers R, Huinink WT. Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood. 1988;65:1373. [PubMed] [Google Scholar]
  • 36.Roth MS, Weiner GJ, Allen EA, Terry WH, Harnden CE, Beohnke M, Kaminski MS, Ginsburg D. Molecular characterization of anti-idiotype antibody-resistant variant of murine B cell lymphoma. J Immunol. 1990;145:768. [PubMed] [Google Scholar]
  • 37.Salmon SE, Seligman M. B cell neoplasia in man. Lancet. 1974;2:1230. doi: 10.1016/s0140-6736(74)90748-x. [DOI] [PubMed] [Google Scholar]
  • 38.Salsano R, Froland SS, Natvig JB, Michaelsen TE. Same idiotype of B-lymphocyte membrane IgD and IgM. Formal evidence for monoclonality of chronic lymphocytic leukemia cells. Scand J Immunol. 1974;3:841. doi: 10.1111/j.1365-3083.1974.tb01321.x. [DOI] [PubMed] [Google Scholar]
  • 39.Schroer KR, Briles DE, Vanboxel JA, Davie JM. Idiotype uniformity of cell surface immunoglobulin in chronic lymphocytic leukemia: evidence for monoclonal proliferation. J Exp Med. 1974;140:1416. doi: 10.1084/jem.140.5.1416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Starnes CO, Carrol WL, Campbell MJ, Houston LL, Apell G, Levy R. Heterogeneity of a murine B cell lymphoma. J Immunol. 1988;141:333. [PubMed] [Google Scholar]
  • 41.Stevenson GT, Stevenson FK. Antibody to a molecularly defined antigen confined to a tumor cell surface. Nature. 1975;254:714. doi: 10.1038/254714a0. [DOI] [PubMed] [Google Scholar]
  • 42.Stevenson GT, Glennie MM, Hamblin TJ, Lane AC, Stevenson FK. Problems and prospects in the use of lymphoma idiotypes as therapeutic targets. Int J Cancer [Suppl] 1988;3:9. doi: 10.1002/ijc.2910410803. [DOI] [PubMed] [Google Scholar]
  • 43.Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975;98:503. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  • 44.Uhr JW. Immunotoxins: a new approach to cancer therapy. Science. 1983;219:649. doi: 10.1126/science.6218613. [DOI] [PubMed] [Google Scholar]
  • 45.Vitetta ES, Yuan D, Krolick KA, Isakson P, Knapp M, Slavin S, Strober S. Characterization of the spontaneous murine B cell leukemia (BCL1): III. Evidence for monoclonality using an anti-idiotype antibody. J Immunol. 1979;122:1649. [PubMed] [Google Scholar]
  • 46.Weiner GJ, Kaminski MS. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. J Immunol. 1989;142:343. [PubMed] [Google Scholar]
  • 47.Wheelock EF, Weinhold KJ, Levich J. The tumor dormant state. Adv Cancer Res. 1981;34:107. doi: 10.1016/s0065-230x(08)60240-7. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES